Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors



Rating:

Share or cite this content

Citations should be made in the following way:
R. Crisan-Dabija (Iasi (Iasi), Romania), C. Grigoras-Ichim (Iasi (Iasi), Romania), A. Luca (Iasi (Iasi), Romania), G. Sandu (Iasi (Iasi), Romania), D. Filipeanu (Iasi (Iasi), Romania). Halotherapy and Covid-19: an oppinion for a possible future prevention approach. 816

Member's Comments

No comment yet.

Related content which might interest you: Other options of prevention - the current state and the future Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches Year: 2003 How to make interventions more successful in the future Source: International Congress 2015 – PG13 Monitoring physical activity Year: 2015 Current and future preventive and treatment strategies in CLAD Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation Year: 2015 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis Source: Eur Respir Monogr 2018; 82: 414-429 Year: 2018 Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios Source: Eur Respir J 2015; 45: 25-29 Year: 2015 How to stop LC-fILD progression: an overview of modern therapeutic strategies Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 What do we need in the clinic and what approach can clinicians take to improve the drug development pipeline? Source: ERS Research Seminar 2016 Year: 2016 Do we need a gender-specific approach for health interventions? Source: Virtual Congress 2021 – Highlights on gender and respiratory health Year: 2021 Using population insight studies to define effective prevention and identification interventions in COPD Source: Annual Congress 2011 - Quality of diagnosis and assessment in primary care Year: 2011 A lifeline for COPD: prevention strategy Source: Breathe 2010; 6: 204-209 Year: 2010 Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention Source: Virtual Congress 2020 – Reducing the burden of asthma Year: 2020 Anti-IgE therapy: current knowledge and future perspective Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 The paradoxes of asthma management: time for a new approach? Source: Eur Respir J, 50 (3) 1701103; 10.1183/13993003.01103-2017 Year: 2017 The future: treating specific endotypes Source: International Congress 2016 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2016 The future: treating specific endotypes Source: International Congress 2015 – PG2 Asthma and COPD Year: 2015 (Non-)sense to interpret meta-analyses with heterogeneous interventions: the example of non-pharmacological interventions Source: International Congress 2015 – How to perform and interpret systematic reviews and meta-analyses Year: 2015